APO Research
Talk to an analyst

APO RESEARCH · REPORT

N-Acetylglutamate Synthetase Deficiency (NAGSD)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Outlook and Growth Opportunities 2026

29 December 2025190 pages

Choose your research edition.

Industry ResearchN-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal N-Acetylglutamate Synthetase Deficiency (NAGSD) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global N-Acetylglutamate Synthetase Deficiency (NAGSD) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the N-Acetylglutamate Synthetase Deficiency (NAGSD) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the N-Acetylglutamate Synthetase Deficiency (NAGSD) market include Grand Pharmaceutical Group, Lee's Pharmaceuticals, Sovereign Medical, Sigmapharm Laboratories, Recordati Rare Diseases, Medunik, Immedica, Amgen and Acer Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global N-Acetylglutamate Synthetase Deficiency (NAGSD) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of N-Acetylglutamate Synthetase Deficiency (NAGSD) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents N-Acetylglutamate Synthetase Deficiency (NAGSD) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global N-Acetylglutamate Synthetase Deficiency (NAGSD) market.

N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Company

Grand Pharmaceutical Group

Lee's Pharmaceuticals

Sovereign Medical

Sigmapharm Laboratories

Recordati Rare Diseases

Medunik

Immedica

Amgen

Acer Therapeutics

N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Type

Original Drug

Generic Drug

N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Application

Adults

Children

N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global N-Acetylglutamate Synthetase Deficiency (NAGSD) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the N-Acetylglutamate Synthetase Deficiency (NAGSD) key companies, revenue, market share, and recent developments.

3. To split the N-Acetylglutamate Synthetase Deficiency (NAGSD) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions N-Acetylglutamate Synthetase Deficiency (NAGSD) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify N-Acetylglutamate Synthetase Deficiency (NAGSD) significant trends, drivers, influence factors in global and regions.

6. To analyze N-Acetylglutamate Synthetase Deficiency (NAGSD) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global N-Acetylglutamate Synthetase Deficiency (NAGSD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of N-Acetylglutamate Synthetase Deficiency (NAGSD) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of N-Acetylglutamate Synthetase Deficiency (NAGSD).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global N-Acetylglutamate Synthetase Deficiency (NAGSD) industry.

Chapter 3: Detailed analysis of N-Acetylglutamate Synthetase Deficiency (NAGSD) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of N-Acetylglutamate Synthetase Deficiency (NAGSD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of N-Acetylglutamate Synthetase Deficiency (NAGSD) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Trends Table 2. N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Drivers Table 3. N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Opportunities and Challenges Table 4. N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Restraints Table 5. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Share by Company (2021-2026) Table 7. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Key Company Manufacturing Base & Headquarters Table 9. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Company, Product Type & Application Table 10. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Original Drug Table 15. Significant Companies of Generic Drug Table 16. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type (2021-2026) Table 20. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Adults Table 22. Significant Companies of Children Table 23. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application (2021-2026) Table 27. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application (2027-2032) Table 28. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Region (2021-2026) Table 31. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Region (2027-2032) Table 33. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Market Share by Country (2021-2026) Table 36. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Market Share by Country (2027-2032) Table 38. Grand Pharmaceutical Group Company Information Table 39. Grand Pharmaceutical Group Business Overview Table 40. Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 42. Grand Pharmaceutical Group Recent Development Table 43. Lee's Pharmaceuticals Company Information Table 44. Lee's Pharmaceuticals Business Overview Table 45. Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 47. Lee's Pharmaceuticals Recent Development Table 48. Sovereign Medical Company Information Table 49. Sovereign Medical Business Overview Table 50. Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 52. Sovereign Medical Recent Development Table 53. Sigmapharm Laboratories Company Information Table 54. Sigmapharm Laboratories Business Overview Table 55. Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 57. Sigmapharm Laboratories Recent Development Table 58. Recordati Rare Diseases Company Information Table 59. Recordati Rare Diseases Business Overview Table 60. Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 62. Recordati Rare Diseases Recent Development Table 63. Medunik Company Information Table 64. Medunik Business Overview Table 65. Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 67. Medunik Recent Development Table 68. Immedica Company Information Table 69. Immedica Business Overview Table 70. Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 72. Immedica Recent Development Table 73. Amgen Company Information Table 74. Amgen Business Overview Table 75. Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 77. Amgen Recent Development Table 78. Acer Therapeutics Company Information Table 79. Acer Therapeutics Business Overview Table 80. Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio Table 82. Acer Therapeutics Recent Development Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Image Figure 2. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021-2032) & (US$ Million) Figure 4. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Original Drug Image Figure 8. Generic Drug Image Figure 9. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type (2021-2032) Figure 12. Adults Image Figure 13. Children Image Figure 14. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application (2021-2032) Figure 17. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value (2021-2032) & (US$ Million) Figure 20. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value (2021-2032) & (US$ Million) Figure 22. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value (2021-2032) & (US$ Million) Figure 26. South America N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Original Drug
  • Generic Drug
Applications
  • Adults
  • Children
Companies covered
  • Grand Pharmaceutical Group
  • Lee's Pharmaceuticals
  • Sovereign Medical
  • Sigmapharm Laboratories
  • Recordati Rare Diseases
  • Medunik
  • Immedica
  • Amgen
  • Acer Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Dynamics
  1. 2.1 N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Trends
  2. 2.2 N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Drivers
  3. 2.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Opportunities and Challenges
  4. 2.4 N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Restraints
3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market by Company
  1. 3.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Company Revenue Ranking in 2025
  2. 3.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Company (2021-2026)
  3. 3.3 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Company Ranking (2024-2026)
  4. 3.4 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Company Manufacturing Base and Headquarters
  5. 3.5 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Company Product Type and Application
  6. 3.6 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 N-Acetylglutamate Synthetase Deficiency (NAGSD) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market by Type
  1. 4.1 N-Acetylglutamate Synthetase Deficiency (NAGSD) Type Introduction
  2. 4.1.1 Original Drug
  3. 4.1.2 Generic Drug
  4. 4.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Type
  5. 4.2.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Type (2021-2032)
  7. 4.2.3 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type (2021-2032)
5 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market by Application
  1. 5.1 N-Acetylglutamate Synthetase Deficiency (NAGSD) Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Application
  5. 5.2.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Application (2021-2032)
  7. 5.2.3 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application (2021-2032)
6 N-Acetylglutamate Synthetase Deficiency (NAGSD) Regional Value Analysis
  1. 6.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Region (2021-2032)
  3. 6.2.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Region: 2021-2026
  4. 6.2.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value (2021-2032)
  7. 6.3.2 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value (2021-2032)
  10. 6.4.2 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value (2021-2032)
  16. 6.6.2 South America N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Country, 2025 VS 2032
7 N-Acetylglutamate Synthetase Deficiency (NAGSD) Country-level Value Analysis
  1. 7.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Country (2021-2032)
  3. 7.2.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Country (2021-2026)
  4. 7.2.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt N-Acetylglutamate Synthetase Deficiency (NAGSD) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Grand Pharmaceutical Group
  2. 8.1.1 Grand Pharmaceutical Group Company Information
  3. 8.1.2 Grand Pharmaceutical Group Business Overview
  4. 8.1.3 Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  6. 8.1.5 Grand Pharmaceutical Group Recent Developments
  7. 8.2 Lee's Pharmaceuticals
  8. 8.2.1 Lee's Pharmaceuticals Company Information
  9. 8.2.2 Lee's Pharmaceuticals Business Overview
  10. 8.2.3 Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  12. 8.2.5 Lee's Pharmaceuticals Recent Developments
  13. 8.3 Sovereign Medical
  14. 8.3.1 Sovereign Medical Company Information
  15. 8.3.2 Sovereign Medical Business Overview
  16. 8.3.3 Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  18. 8.3.5 Sovereign Medical Recent Developments
  19. 8.4 Sigmapharm Laboratories
  20. 8.4.1 Sigmapharm Laboratories Company Information
  21. 8.4.2 Sigmapharm Laboratories Business Overview
  22. 8.4.3 Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  24. 8.4.5 Sigmapharm Laboratories Recent Developments
  25. 8.5 Recordati Rare Diseases
  26. 8.5.1 Recordati Rare Diseases Company Information
  27. 8.5.2 Recordati Rare Diseases Business Overview
  28. 8.5.3 Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  30. 8.5.5 Recordati Rare Diseases Recent Developments
  31. 8.6 Medunik
  32. 8.6.1 Medunik Company Information
  33. 8.6.2 Medunik Business Overview
  34. 8.6.3 Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  36. 8.6.5 Medunik Recent Developments
  37. 8.7 Immedica
  38. 8.7.1 Immedica Company Information
  39. 8.7.2 Immedica Business Overview
  40. 8.7.3 Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  42. 8.7.5 Immedica Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  48. 8.8.5 Amgen Recent Developments
  49. 8.9 Acer Therapeutics
  50. 8.9.1 Acer Therapeutics Company Information
  51. 8.9.2 Acer Therapeutics Business Overview
  52. 8.9.3 Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
  54. 8.9.5 Acer Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst